肝细胞癌门静脉癌栓肿瘤反应的观察性研究
An observational study on tumour response of portal vein tumour thrombus in hepatocellular carcinoma.
作者信息
Mehra Prateek, Kataria Tejinder, Gupta Deepak, Krishan Sonal
机构信息
Division of Radiation Oncology, Medanta the Medicity, Gurgaon, Haryana, 122001, India.
Department of Radiology and Nuclear Medicine, Medanta the Medicity, Gurgaon, Haryana, 122001, India.
出版信息
J Radiosurg SBRT. 2022;8(4):257-264.
OBJECTIVES
Stereotactic body radiotherapy (SBRT) can sterilize the portal vein tumour thrombus (PVTT) and may make the patient eligible for liver transplant. We assessed the radiological response of PVTT after SBRT and check incidence of radiation induced liver disease (RILD).
METHODS
PVTT treatment response was measured at 4-6 weeks as per mRECIST criteria, volume of PVTT and its enhancement in arterial phase. Biochemical data and Child-Pugh scoring (CPC) were evaluated to determine RILD incidence.
RESULTS
31 Patients were included. Complete response was seen in 5 patients (16.1%), partial response in 13 patients (41.9%), stable disease in 12 patients (38.7%). Mean volume of PVTT was 15.05 cc before SBRT and 7.83 cc afterwards (p = 0.001). The mean enhancement of the lesion was 86.19HU before SBRT vs 58.58HU after SBRT (p = 0.000). Two patients had grade 3 adverse events.
CONCLUSION
Volume, enhancement, and major axis length of PVTT showed statistically significant improvement after SBRT. No case had RILD after SBRT.
目的
立体定向体部放疗（SBRT）可使门静脉肿瘤血栓（PVTT）失活，并可能使患者符合肝移植条件。我们评估了SBRT后PVTT的放射学反应，并检查放射性肝病（RILD）的发生率。
方法
根据mRECIST标准，在4-6周时测量PVTT的治疗反应、PVTT体积及其动脉期强化情况。评估生化数据和Child-Pugh评分（CPC）以确定RILD的发生率。
结果
纳入31例患者。5例（16.1%）患者达到完全缓解，13例（41.9%）患者部分缓解，12例（38.7%）患者病情稳定。SBRT前PVTT平均体积为15.05立方厘米，SBRT后为7.83立方厘米（p = 0.001）。SBRT前病变的平均强化值为86.19HU，SBRT后为58.58HU（p = 0.000）。2例患者发生3级不良事件。
结论
SBRT后PVTT的体积、强化和长径有统计学意义的改善。SBRT后无RILD病例。
Zotero 插件